


What is claimed is:

1. A compound according to formula (I) below, having the structure:




Formula (I)

wherein:


R^1 is selected from the group consisting of hydrogen, halogen, C_{1-4} alkyl, C_{1-4} alkanoyl and aroyl;

G^1 represents CH_2-CH_2 or $CH=CH$;


G^2 represents C_{4-7} alkyl or a group of the formula (a), (b) or (c):



(a)




(b)




(c)

;


X represents a group of the formula (d), (e) or (f):



(d)



(e)



(f)

wherein

Y is, independently, selected from the group consisting of a bond, O, S, NR^2 , $-NR^2-$, C_{1-4} alkyl-, and C_{1-4} alkyl- each of these alkyl groups may contain a heteroatom selected from O, NR^2 , or S;

R^2 represents a hydrogen, C_{1-4} alkyl or C_{1-4} alkyl-aryl;

Ar, Ar^1 and Ar^2 are, independently, selected from the group consisting of an optionally substituted phenyl rings, optionally substituted 5- or 6- membered aromatic heterocyclic rings or optionally substituted, fused bicyclic or tricyclic aromatic or heteroaromatic ring systems;

L is, independently, selected from the group consisting of a bond, optionally substituted C_{1-4} alkanoyl, C_{1-4} alkenyl, C_{1-4} alkynyl or C_{1-18} alkyl which may contain between 0 and 3 heteroatoms independently selected from O, NR^2 , or S;

Also, atoms within L may be joined to form up to 3 rings and additionally L may be have up to 3 aryl, heteroaryl or $-\text{CO}_2\text{R}^2$ substituents;

Z represents a bond, O, NR^2 , S, C_{1-4} alkylidene or C_{1-4} alkyl.

2. A compound according to claim 1 selected from the group consisting of:
 N-{4-[2-(-(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl)-ethyl]-cyclohexyl}-2-[2-(-(4-[2-(-(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl)-ethyl)-cyclohexylcarbamoyl)-methyl)-phenyl]-acetamide;
 2,2'-benzene-1,3-diylbis[N-(*trans*-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)acetamide];
 N-(*trans*-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-N'-{4-[[[(*trans*-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)amino]carbonyl]amino)methyl]phenyl}urea;
 N,N''-(benzene-1,3-diyl)dimethanediylbis[N-(*trans*-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-1,2-propanediylbis[N-(*trans*-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-1,6-hexanediylbis[N-(*trans*-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-[(methylimino)di-2,1-ethanediyl]bis[N-(*trans*-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-1,2-butanediylbis[N-(*trans*-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N-(*trans*-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-N''-{15-[(*trans*-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)amino]-15-oxo-4,7,10-trioxa-14-azapentadec-1-yl}urea;
 N',N'''-1,4-butanediylbis[N-(*trans*-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-(thiodi-2,1-ethanediyl)bis[N-(*trans*-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-1,2-ethanediylbis[N-(*trans*-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];

N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-N'-[3-({[(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)amino]carbonyl}amino)-2,2-dimethylpropyl]urea;
 N',N'''-1,2-cyclohexanediylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 2,2'-benzene-1,4-diylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)acetamide] trifluoroacetate;
 2,2'-benzene-1,3-diylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)acetamide] trifluoroacetate;
 N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-N'-{[5-({[2-({[(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)amino]carbonyl}amino)ethyl]thio}methyl)-2-furanyl]methyl}urea;
 N',N'''-(2,3-naphthalenediylldimethanediyl)bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-1,12-dodecanediylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-[benzene-1,2-diylbis(oxy-2,1-ethanediyl)]bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-(benzene-1,3-diylldi-2,1-ethanediyl)bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-(benzene-1,4-diylldi-2,1-ethanediyl)bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-(1,3-cyclohexanediylldimethanediyl)bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-1,11-undecanediylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-1,10-decanediylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-1,8-octanediylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-[1,1'-bi(cyclohexyl)-4,4'-diylbis(oxy-2,1-ethanediyl)]bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];

N',N'''-(dithiodi-3,1-propanediyl)bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate and pharmaceutically acceptable salts thereof.

3. A compound according to claim 1 selected from the group consisting of:

N',N'''-(1,4-cyclohexanediyldimethanediyl)bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-[3-(1H-indol-3-yl)-1,2-propanediyl]bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-1,7-heptanediylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-N'-[2-({[(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)amino]carbonyl}amino)-3-cyclohexyl-2-(hydroxymethyl)propyl]urea trifluoroacetate;
 N',N'''-[oxybis(benzene-4,1-diyl-1,1-ethanediyl)]bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-[oxybis(benzene-4,1-diyl-1,1-propanediyl)]bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-[(E)-1,2-ethenediylbis(benzene-4,1-diylmethanediyl)]bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-[(1R,2R)-1,2-diphenyl-1,2-ethanediyl]bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-(9,10-anthracenediyl-di-2,1-ethanediyl)bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-2,11-dodecanediylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate;
 N',N'''-(dithiodi-2,1-ethanediyl)bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N~3~-{[(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)amino]carbonyl}-N~1~-{[3-({[(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)amino]carbonyl}amino)propyl]-beta-alaninamide;

N',N'''-2-butyne-1,4-diylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-1,2-cyclopropanediylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-2,3-butanediylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-[1,2-ethanediylbis(oxy-2,1-ethanediyl)]bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-1,3-propanediylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-1,9-nonanediylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-N'-(3-{10-[2-({[(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)amino]carbonyl}amino)ethyl]-9-anthracenyl}propyl)urea;
 N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-N'-(3-{4-({[(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)amino]carbonyl}amino)butyl}(phenylmethyl)amino)propyl)urea;
 N',N'''-1,5-pentanediylbis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-(3-oxo-1,5-pentanediyl)bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-(dithiodi-4,1-butanediyl)bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 methyl N~2~,N~6~-bis[{(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)amino]carbonyl}-L-lysinate;
 ethyl N~2~,N~6~-bis[{(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)amino]carbonyl}lysinate;
 N',N'''-[benzene-1,3-diylbis(oxy-3,1-propanediyl)]bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-[benzene-1,2-diylbis(oxy-3,1-propanediyl)]bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];

N',N'''-[(1R,7R)-tricyclo[5.2.1.0~2,6~]decane-3,8-diyl dimethanediyl]bis[N-(trans-4-{2-
 [(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea];
 N',N'''-[(methylimino)di-3,1-propanediyl]bis[N-(trans-4-{2-[(1R,8S)-11-
 azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)urea] trifluoroacetate
 (2E)-N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-
 yl]ethyl}cyclohexyl)-4-oxo-4-phenyl-2-butenamide;
 N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-
 yl]ethyl}cyclohexyl)-2,6-pyridinedicarboxamide trifluoroacetate;
 2,2'-oxybis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-
 yl]ethyl}cyclohexyl)acetamide] trifluoroacetate;
 N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-
 yl]ethyl}cyclohexyl)-2,3-pyrazinedicarboxamide trifluoroacetate;
 N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-
 yl]ethyl}cyclohexyl)-3,4-pyridinedicarboxamide trifluoroacetate;
 N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-
 yl]ethyl}cyclohexyl)-1,3-benzenedicarboxamide trifluoroacetate;
 N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-
 yl]ethyl}cyclohexyl)-3,5-pyridinedicarboxamide trifluoroacetate;
 2,2'-(1,1-cyclopentanediy)bis[N-(trans-4-{2-[(1R,8S)-11-
 azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)acetamide]
 trifluoroacetate;
 N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-
 yl]ethyl}cyclohexyl)-2,3-dimethylbutanediamide trifluoroacetate;
 N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-
 yl]ethyl}cyclohexyl)-2,5-thiophenedicarboxamide trifluoroacetate;
 N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-
 yl]ethyl}cyclohexyl)-2-phenylbutanediamide trifluoroacetate;
 N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-
 yl]ethyl}cyclohexyl)-4-({2-[(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-
 2,4,6-trien-11-yl]ethyl}cyclohexyl)amino]-2-oxoethyl}oxy)benzamide trifluoroacetate;
 N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-
 yl]ethyl}cyclohexyl)-3,3-dimethylpentanediamide trifluoroacetate;
 2,2'-(methylimino)bis[N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-
 trien-11-yl]ethyl}cyclohexyl)acetamide] trifluoroacetate;

N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-2,3-thiophenedicarboxamide trifluoroacetate;
N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-2-{3-[(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)amino]-3-oxopropyl}benzamide trifluoroacetate;
N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-2,5-furandicarboxamide trifluoroacetate;
N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-1,2-cyclohexanedicarboxamide trifluoroacetate;
N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-1,3-cyclohexanedicarboxamide trifluoroacetate;
N-(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-4-{3-[(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)amino]-3-oxopropyl}benzamide trifluoroacetate;
N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-2,2-dimethyl-1,3-cyclobutanedicarboxamide trifluoroacetate;
N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-1,3-cyclopentanedicarboxamide trifluoroacetate;
N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-2,2-dimethylbutanediamide trifluoroacetate;
N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-2-(phenylmethyl)propanediamide trifluoroacetate;
N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-2,2-diethylpropanediamide trifluoroacetate;
N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-1,2-cyclopropanedicarboxamide trifluoroacetate;
N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-1,4-cyclohexanedicarboxamide trifluoroacetate;
N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)butanediamide trifluoroacetate;
N,N'-bis(trans-4-{2-[(1R,8S)-11-azatricyclo[6.2.1.0^{2,7}]undeca-2,4,6-trien-11-yl]ethyl}cyclohexyl)-2,3-pyridinedicarboxamide trifluoroacetate and pharmaceutically acceptable salts thereof.

4. A pharmaceutical composition for the treatment of muscarinic acetylcholine receptor mediated diseases comprising a compound according to claim 1 and a pharmaceutically acceptable carrier thereof.
5. A method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof comprising administering a safe and effective amount of a compound according to claim 1.
6. A method of treating a muscarinic acetylcholine receptor mediated disease, wherein acetylcholine binds to said receptor, comprising administering a safe and effective amount of a compound according to claim 1.
7. A method according to claim 6 wherein the disease is selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
8. A method according to claim 7 wherein administration is via inhalation via the mouth or nose.
9. A method according to claim 8 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.
10. A method according to claim 9 wherein the compound is administered to a human and has a duration of action of 12 hours or more for a 1 mg dose.
11. A method according to claim 10 wherein the compound has a duration of action of 24 hours or more.
12. A method according to claim 11 wherein the compound has a duration of action of 36 hours or more.